Form 4: Teva Pharmaceutical Industries Director Janet S. Vergis Reports Share Transactions
SEC Form 4 Filing
Director Janet S. Vergis reports the vesting and disposal of restricted share units resulting in the acquisition and disposal of ordinary shares of Teva Pharmaceutical Industries.
Summary
- On June 15, 2024, Janet S. Vergis, a director of Teva Pharmaceutical Industries Ltd., reported transactions involving ordinary shares and restricted share units.
- Vergis disposed of 21,108 ordinary shares upon the vesting of restricted share units.
- The restricted share units, granted on June 15, 2023, vested on June 15, 2024.
- Following the reported transactions, Vergis beneficially owns 64,065 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions by a company director, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and does not necessarily reflect a significant event for Teva Pharmaceutical Industries or the broader pharmaceutical industry.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 06/15/2023 | Restricted Share Units were granted. |
| 06/15/2024 | Restricted Share Units vested and shares were disposed of. |
| 06/17/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.